Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors

长期乙醇暴露与神经元烟碱乙酰胆碱受体

基本信息

项目摘要

DESCRIPTION (provided by applicant): Alcohol use disorders impact millions of individuals and constitute one of the most serious public health problems worldwide. Despite its devastating impact on society, there are still few effective medications currently available. It is well-known that alcohol and nicotine are commonly abused together, and that ethanol and nicotine have direct affects on neuronal nicotinic acetylcholine receptors (nAChRs). These receptors have been shown to modulate the mesolimbic dopamine system and contribute to the reinforcing actions of both ethanol and nicotine. The nAChRs are pentameric ligand-gated ion channels and in the CNS there are at least twelve receptors, designated 12 to 110, and 22 to 24 that assemble into multiple combinations. My lab discovered that varenicline, a drug that primarily binds to 1422 nAChRs and approved by the FDA as a smoking cessation aid, reduces ethanol self-administration and heavy drinking following long-term ethanol exposure. We will determine the consequences of long-term ethanol exposure on the role and expression of 1422 nAChRs following voluntary heavy ethanol consumption, operant self-administration and in stress- induced reinstatement. We will integrate behavioral and biochemical techniques to identify the brain regions mediating the effects of long-term ethanol exposure on the expression of nAChRs. The long-term goal is to design better therapeutic agents that target nAChRs for the treatment of alcohol use disorders. PUBLIC HEALTH RELEVANCE: Alcohol use disorders are one of the most serious public health problems worldwide. Neuronal nicotinic acetylcholine receptors (nAChRs) have been shown to contribute to the effects of ethanol. We found that varenicline, a modulator of 1422 nAChRs and recently approved as an aid for smoking cessation, reduces ethanol self-administration and heavy drinking following long-term but not short-term ethanol exposure. We will determine whether long-term ethanol exposure induces changes in the expression of 1422 nAChRs and whether this contributes to the reinforcing effects of ethanol and/or stress-induced relapse. The long-term goal is to design more selective and effective medications for the treatment of alcohol use disorders.
描述(由申请人提供): 酒精使用障碍影响着数百万人,并构成全球最严重的公共卫生问题之一。尽管它对社会造成了毁灭性的影响,但目前仍然几乎没有有效的药物可用。众所周知,酒精和尼古丁经常一起滥用,乙醇和尼古丁对神经元烟碱型乙酰胆碱受体(NAChRs)有直接影响。这些受体已被证明调节中脑边缘多巴胺系统,并有助于乙醇和尼古丁的增强作用。NAChRs是五聚体配体门控离子通道,在中枢神经系统中至少有12个受体,分别命名为12到110和22到24,它们组装成多种组合。我的实验室发现,varenicline,一种主要与1422 nAChRs结合的药物,并被FDA批准为戒烟辅助药物,可以减少长期酒精暴露后的酒精自我给药和大量饮酒。我们将确定长期酒精暴露对1422nAChRs的作用和表达的影响,在自愿大量酒精摄入、操作性自我管理和应激诱导的恢复过程中。我们将结合行为和生化技术来确定调节长期酒精暴露对nAChRs表达影响的大脑区域。长期目标是设计更好的针对nAChRs的治疗剂来治疗酒精使用障碍。 公共卫生相关性:酒精使用障碍是全球最严重的公共卫生问题之一。神经元烟碱型乙酰胆碱受体(NAChRs)已被证明与乙醇的作用有关。我们发现,varenicline,一种1422 nAChRs的调节剂,最近被批准作为戒烟的辅助药物,在长期但不是短期的酒精暴露后,减少了乙醇自我给药和大量饮酒。我们将确定长期酒精暴露是否会导致1422nAChRs表达的变化,以及这是否有助于酒精和/或应激诱导的复发的增强效应。长期目标是设计更有选择性和更有效的药物来治疗酒精使用障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Selena E. Bartlett其他文献

Dissecting the contribution of 5-HTsub1A/sub auto- and heteroreceptors in sucrose overconsumption in mice
剖析 5-羟色胺 1A 自身受体和 5-羟色胺 1A 异源受体在小鼠蔗糖过度消耗中的贡献
  • DOI:
    10.1016/j.biopha.2022.112699
  • 发表时间:
    2022-04-01
  • 期刊:
  • 影响因子:
    7.500
  • 作者:
    Kate Beecher;Joshua Wang;Fatemeh Chehrehasa;Ronan Depoortere;Mark A. Varney;Adrian Newman-Tancredi;Selena E. Bartlett;Arnauld Belmer
  • 通讯作者:
    Arnauld Belmer
A chimeric approach to evaluate the role of corticotropin releasing factor in alcohol use disorder
  • DOI:
    10.1016/j.alcohol.2017.02.267
  • 发表时间:
    2017-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Carolina L. Haass-Koffler;Andrea T. Henry;Gerd Melkus;Jeffrey A. Simms;Mohammed Naemmuddin;Carsten K. Nielsen;Amy W. Lasek;Molly Magill;Melanie L. Schwandt;Reza Momenan;Colin A. Hodgkinson;Selena E. Bartlett;Robert M. Swift;Antonello Bonci;Lorenzo Leggio
  • 通讯作者:
    Lorenzo Leggio

Selena E. Bartlett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Selena E. Bartlett', 18)}}的其他基金

Developing Medications for Nicotine Cessation
开发戒烟药物
  • 批准号:
    8261057
  • 财政年份:
    2011
  • 资助金额:
    $ 39.62万
  • 项目类别:
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes
鉴定 CRF 结合蛋白和 CRF 受体复合物的化学调节剂
  • 批准号:
    7999293
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes
鉴定 CRF 结合蛋白和 CRF 受体复合物的化学调节剂
  • 批准号:
    8107634
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors
长期乙醇暴露与神经元烟碱乙酰胆碱受体
  • 批准号:
    8576024
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Characterizing Alpha5* Nicotinic Receptors in Alcohol and Nicotine Co-Dependence
酒精和尼古丁相互依赖性中 Alpha5* 烟碱受体的特征
  • 批准号:
    7855783
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors
长期乙醇暴露与神经元烟碱乙酰胆碱受体
  • 批准号:
    8608471
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Characterizing Alpha5* Nicotinic Receptors in Alcohol and Nicotine Co-Dependence
酒精和尼古丁相互依赖性中 Alpha5* 烟碱受体的特征
  • 批准号:
    7944068
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors
长期乙醇暴露与神经元烟碱乙酰胆碱受体
  • 批准号:
    8197679
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors
长期乙醇暴露与神经元烟碱乙酰胆碱受体
  • 批准号:
    7994236
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors
长期乙醇暴露与神经元烟碱乙酰胆碱受体
  • 批准号:
    8387715
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了